Skandigen Interim report January - September 1996

Skandigen Interim report January - September 1996 - The Group's sales amounted to MSEK 13.3 (11.0) for the period. The consolidated result after depreciation was MSEK -5.3 (-9.2). The result after net financial items amounted to MSEK 5.8 (-9.5). The net financial items include a non-recurring revenue from sale of subscription warrants of MSEK 10.2 (0). - The subsidiary Fermentech Medical Ltd. got approval in October to start clinical trials of its hyaluronan product for treatment of osteoarthritis. ------------------------------------------------------------ This information was brought to you by Waymaker

About Us

Skanditek is an industry holding company with ownership interests mainly in Swedish unlisted companies. The portfolio comprises some twenty holdings with focus on information technology, electronics and industrial components.